Home

Investor Relations

Company Overview

Canada’s most awarded licensed producer, Aurora Cannabis’ wholly owned subsidiary MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.

Latest News

25 Jul 2018.
Aurora Cannabis and MedReleaf Close the World's Largest Cannabis Industry Transaction Canada Newswire Creating a Global Industry Leader Positioned for Long-Term, Accelerated Growth TSX: ACB TSX: LEAF EDMONTON , July 25, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and MedReleaf Corp. ("MedReleaf") (TSX: LEAF) today announced the closing of the previously announced arrangement agreement (the "Arrangement Agreement"). Under the terms of the Arrangement Agreement, holders of MedReleaf common shares received 3.575 common shares of Aurora for each MedReleaf common share held (the "Exchange Ratio"). Upon closing of the transaction, Aurora will submit applications with the Toronto Stock Exchange (the "TSX") and the Ontario Securities Commission (the "OSC") to delist MedReleaf's existing common shares and for MedReleaf to cease to be a reporting issuer, respectively. Management Commentary "The closing of this transaction brings ...
24 Jul 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") today announced that it has acquired MED Colombia SAS ("MED Colombia"), a company with licences in Colombia to cultivate cannabis and produce cannabis oil extracts, along with a library of cannabis genetics, for a total consideration of €2.75 million in cash. This acquisition provides MedReleaf with the ability to produce low-cost, high-quality raw materials to serve its global supply chain as well as the domestic Colombian medical cannabis market. "As the legalization of medical cannabis continues to expand, we must ensure that our ability to cultivate cost effectively extends beyond Canada to supply our global operations," said Neil Closner, CEO of MedReleaf. "Colombia has one of the best climates in the world for cannabis cultivation and excellent regulation to protect the rights of growers and operators. With the acquisition of MED Colombia we continue to execute on our international strategy and will be well positioned to ...
20 Jul 2018.
MedReleaf Corp. ("MedReleaf") (TSX: LEAF) today announced that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving its previously announced plan of arrangement (the "Arrangement") pursuant to which Aurora Cannabis Inc. ("Aurora") agreed to acquire all of the issued and outstanding common shares of MedReleaf for 3.575 common shares of Aurora and $0.000001 in cash in exchange for each MedReleaf common share held. The closing of the Arrangement remains subject to certain customary closing conditions. Assuming the timely satisfaction of these closing conditions, the Arrangement is expected to close on or about July 25, 2018. Shareholders who have questions or require assistance with submitting their shares to the Arrangement, including with respect to completing the applicable letter of transmittal, are asked to contact Computershare Investor Services Inc., who is acting as depositary under the Arrangement, toll free at 1-800-564-6253 or by email at ...